Compare MasterCard Inc (MA) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs ResMed Inc. — how do they compare? MasterCard Inc trades at $538.19 (market cap $483.71B), while ResMed Inc. trades at $194.03 (market cap $28.81B). The key difference: MasterCard Inc is far larger — about 16.8× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.21%). Which is the better fit depends on your goals.
| MA | RMD | |
|---|---|---|
Market Cap | $483.71B | $28.81B |
Volume | 4,635,698 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $598.96 | $293.73 |
52-Week Low | $471.55 | $182.82 |
Enterprise Value | $494.45B | $27.99B |
Dividend Yield | 0.64% | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $538.30, down 0.97% on the day, with a bullish technical outlook supported by moving averages and strong price targets. The company demonstrates robust fundamentals with revenue growth from $32.79B in 2025 to a projected $33.9B in 2026, net income margins above 45%, and consistent earnings beats. Recent news highlights institutional buying and strategic initiatives in AI and financial inclusion.
The outlook remains positive given Wall Street's strong buy consensus and a $634.27 price target, though high valuation multiples and competitive disruption from new payment technologies present risks. Earnings growth and market leadership are key catalysts for upside.
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
